Immunoglobulin light chain amyloidosis
- 18 December 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Hematology
- Vol. 7 (1), 143-156
- https://doi.org/10.1586/17474086.2014.858594
Abstract
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage. Accurate diagnosis requires clinical skills and advanced technologies. The disease can be halted and the function of target organs preserved by the prompt reduction and elimination of the plasma cell clone producing the toxic light chains in the bone marrow. Heart damage is the major determinant of survival, and staging with cardiac biomarkers guides treatment. Two-thirds of patients can benefit from treatment with improved quality of life and extended survival. Future efforts should be directed at early diagnosis, improving the tolerability and efficacy of anti-plasma cell therapy, accelerating recovery of organ function via promoting resorption of amyloid deposits, and developing novel approaches to counter light chain proteotoxicity.Keywords
This publication has 100 references indexed in Scilit:
- Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interactionBiophysical Chemistry, 2011
- In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptidesProceedings of the National Academy of Sciences of the United States of America, 2011
- Preclinical development of siRNA therapeutics for AL amyloidosisGene Therapy, 2011
- Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and FibrilsPublished by Elsevier BV ,2010
- Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart FailureTransplantation, 2010
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- Kidney dysfunction during lenalidomide treatment for AL amyloidosisNephrology Dialysis Transplantation, 2010
- Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugsAmerican Journal of Hematology, 2010
- Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathwayProceedings of the National Academy of Sciences of the United States of America, 2010
- Kinetic Analysis of Amyloid Formation in the Presence of Heparan SulfateJournal of Biological Chemistry, 2009